Mural Oncology plc announces the effectiveness of the scheme of arrangement for its acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation.
The acquisition involves the acquisition of the entire issued and to be issued share capital of Mural by Sub.
Distribution of cash consideration to Scheme Shareholders is expected to begin soon after the Effective Date.
Scheme of Arrangement Effective
The scheme of arrangement for Mural's acquisition by XRA 5 Corp. has become effective on December 5, 2025.
Acquisition by XOMA Royalty
XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, is acquiring Mural Oncology plc.
Distribution of Consideration
Cash consideration to Scheme Shareholders is expected to be distributed by December 19, 2025.
- The completion of the acquisition marks a significant milestone for Mural Oncology plc and its shareholders.
- This transaction strengthens the position of XOMA Royalty Corporation in the market.
- Investors and stakeholders can expect changes in the shareholder structure and strategic direction of Mural Oncology.
The acquisition and scheme of arrangement represent a strategic move for both Mural Oncology plc and XOMA Royalty Corporation, leading to potential growth opportunities and enhanced value for shareholders.